Dual HER2 targeting for early breast cancer
Mené sur 529 patientes atteintes d'un cancer du sein HER2+ opérable, cet essai de phase III évalue l'efficacité, du point de vue de la réponse pathologique complète, et la toxicité du lapatinib, en combinaison avec une chimiothérapie et/ou du trastuzumab, en traitement néoadjuvant
Neoadjuvant (preoperative) chemotherapy is used for the treatment of locally advanced or large operable early breast cancer to downstage the primary tumour and increase the chance of successful breast-conserving surgery. In addition, it has become a useful setting for the assessment of new anticancer therapies, with pathological complete response (pCR) as a surrogate endpoint for treatment efficacy. A recent meta-analysis of collaborative trials in neoadjuvant breast cancer confirmed that patien ...
The Lancet Oncology , commentaire, 2012